Trametinib and combination decrease T-lymphocyte proliferation.

Slides:

Advertisements

Similar presentations

Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Advertisements

Uptake of T-MPs for DC maturation and antigen presentation.

A B Supplementary Figure 3

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

The inhibition of PI3K and Akt in human T cells selectively inhibits the proliferation of human Tregs compared with Tconvs in a dose-dependent manner.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

PVSRIPO-mediated APC activation occurs in immunosuppressive conditions

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Suppressive effect of CD39+CD73+ melanoma cells on T-cell proliferation, and reversion of this effect via treatment with the CD39-blocking antibody, CD39.

A, RT-qPCR of ROR1 mRNA expression in B-CLL cells and a panel of human and rhesus macaque tissues. A, RT-qPCR of ROR1 mRNA expression in B-CLL cells and.

DC-derived EV differentiate monocytes.

BRAFV600E promotes glycolysis in melanoma cells via regulation of GLUT1, GLUT3, and HK2. BRAFV600E promotes glycolysis in melanoma cells via regulation.

Effect of antiangiogenic TKIs and rMVA–CEA–TRICOM vaccine on tumor compactness, tight junctions, and intratumoral pressure in the MC38-CEA model. Effect.

mpJX-594 effects on tumor burden and leukocyte influx.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

IL-6 neutralization decreases T cell proliferation and cytokine production upon restimulation by allogeneic HUVEC. CIITA transduced HUVECs were cocultured.

Differential expression of TRM markers by donor- and recipient-derived T cells with time. Differential expression of TRM markers by donor- and recipient-derived.

Effect of CD4+ Th1 cytokines and HER2-targeted antibodies on MHC class I restoration and HER2369–377-CD8+ T-cell targeting of HER2-expressing cancer cells.

PD-1 blockade enhances T-cell function.

MK-8628 suppresses T lymphocyte proliferation.

MK-8628 promotes T lymphocyte cell cycle arrest.

T-CTLs are CD8+ TEMRA cells that can be expanded by IL-15 and IL-2 through selective proliferation and can be induced by LCs. T-CTLs are CD8+ TEMRA cells.

MK-8628 augments T lymphocyte apoptosis.

PTX in combination with PLX397 induces antitumor T-cell response.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

The TSDR of ATL cells exhibits Treg-like hypomethylated status or CD4+ conventional T cell–like methylated status. The TSDR of ATL cells exhibits Treg-like.

HRI depletion elevates γ-globin in primary erythroid CD34+ cells

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

pDCs from the melanoma environment responded to TLR-L stimulation.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Immunohistochemistry for phosphorylated (S235) S6 ribosomal protein and quantitation of Ki67 labeling indices in vehicle- and WAY –treated Eker (Tsc2+/−)

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

ALT-803 stimulates proliferation and activation of human NK cells and T cells in vitro. ALT-803 stimulates proliferation and activation of human NK cells.

Uptake of TEX by DCs in vivo.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

Canonical but not adaptive NK-cell function is suppressed by Tregs.

Immunologic and pharmacokinetic studies.

Ketogenic diets combined with fractionated radiation treatment results in decreased immunoreactive PCNA in tumor tissue. Ketogenic diets combined with.

Neutralization of CSF1 and Ad5-HRG treatment.

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1, 2, or 3 days after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c.

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

CD19-CAR-T cells with short and long spacers show specific in vitro function. CD19-CAR-T cells with short and long spacers show specific in vitro function.

PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate distinct mechanisms of regulation. PD-1 and CD103 are coexpressed on CD8+ T cells but demonstrate.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Trametinib and combination promote moDC maturation and decrease moDC viability. Trametinib and combination promote moDC maturation and decrease moDC viability.

A CD3 gate B C D Supplementary Figure 1. Characterization of airway cells for transfer. BALB/c mice were infected twice with 105 pfu RSV with 21 day recovery.

Local proliferation of infiltrating circulating memory T cells.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

AR inhibition decreases ER+/AR+ breast cancer growth.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

AXL overexpression decreases proliferation in vitro.

IL35 regulation of tumor growth is accompanied by suppression of CD4+ effector T-cell activity and expansion of Tregs. IL35 regulation of tumor growth.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

IL-9–expressing TH cells are highly enriched in CCR4+/CCR8+ effector memory TH cells. IL-9–expressing THcells are highly enriched in CCR4+/CCR8+effector.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells. Curcumin decreases viability and proliferation of Bcr-Abl-expressing cells.

Phenotypic diversity of less predominant B-lineage clones.

Comparison of MLTC responses to tumor/peptide stimuli at day 18 and day 34 of growth. Comparison of MLTC responses to tumor/peptide stimuli at day 18 and.

Bezafibrate increases the number of effector CTLs by enhancing their survival capacity and proliferation. Bezafibrate increases the number of effector.

Varying the MHC-I affinity, TCR affinity or antigen dose alters the phenotype of CD8 T cells ex vivo. Varying the MHC-I affinity, TCR affinity or antigen.

Phenotyping of T cells. Phenotyping of T cells. Circulating lymphocytes from a tumor-naïve C57BL/6 mice (left column) were compared with those from C57BL/6.

Presentation transcript:

Trametinib and combination decrease T-lymphocyte proliferation. Trametinib and combination decrease T-lymphocyte proliferation. The proliferation index (A and C) and viability (B and D) of CD3/CD28-activated CFSE-labeled CD4+ (A and C) and CD8+ (B and D) T cells treated for 5 days with dabrafenib or trametinib, alone or in combination. Each point represents the mean value from the results obtained with 4 healthy donors; error bars show the SEM. One-way ANOVA with a Dunnett post test against the untreated control was performed. *, P < 0.05; **, P < 0.01; ***, P < 0.001. The proliferation index was determined using the proliferation tool in the FlowJo software package. This value represents the average number of cell divisions that the cells underwent by considering only the fraction of proliferated cells. Dabrafenib, BRAFi; trametinib, MEKi. Representative flow cytometry data are presented in Supplementary Fig. S1. Laura J. Vella et al. Cancer Immunol Res 2014;2:351-360 ©2014 by American Association for Cancer Research